Unknown

Dataset Information

0

Ultraefficient extracellular vesicle-guided direct reprogramming of fibroblasts into functional cardiomyocytes.


ABSTRACT: Direct lineage conversion holds great promise in the regenerative medicine field for restoring damaged tissues using functionally engineered counterparts. However, current methods of direct lineage conversion, even those using virus-mediated transgenic expression of tumorigenic factors, are extremely inefficient (~25%). Thus, advanced methodologies capable of revolutionizing efficiency and addressing safety concerns are key to clinical translation of these technologies. Here, we propose an extracellular vesicle (EV)-guided, nonviral, direct lineage conversion strategy to enhance transdifferentiation of fibroblasts to induced cardiomyocyte-like cells (iCMs). The resulting iCMs have typical cardiac Ca2+ transients and electrophysiological features and exhibit global gene expression profiles similar to those of cardiomyocytes. This is the first demonstration of the use of EVs derived from embryonic stem cells undergoing cardiac differentiation as biomimetic tools to induce cardiac reprogramming with extremely high efficiency (>60%), establishing a general, more readily accessible platform for generating a variety of specialized somatic cells through direct lineage conversion.

SUBMITTER: Kim H 

PROVIDER: S-EPMC8880777 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ultraefficient extracellular vesicle-guided direct reprogramming of fibroblasts into functional cardiomyocytes.

Kim Hyosuk H   Song Byeong-Wook BW   Park Soon-Jung SJ   Choi Seong Woo SW   Moon Hanbyeol H   Hwang Ki-Chul KC   Kang Sun-Woong SW   Moon Sung-Hwan SH   Yang Yoosoo Y   Kwon Ick Chan IC   Kim Sun Hwa SH  

Science advances 20220225 8


Direct lineage conversion holds great promise in the regenerative medicine field for restoring damaged tissues using functionally engineered counterparts. However, current methods of direct lineage conversion, even those using virus-mediated transgenic expression of tumorigenic factors, are extremely inefficient (~25%). Thus, advanced methodologies capable of revolutionizing efficiency and addressing safety concerns are key to clinical translation of these technologies. Here, we propose an extra  ...[more]

Similar Datasets

2022-03-02 | GSE166251 | GEO
| S-EPMC2919844 | biostudies-literature
2022-03-02 | GSE166250 | GEO
2022-03-02 | GSE166249 | GEO
| S-EPMC4559819 | biostudies-literature
| PRJNA699851 | ENA
| S-EPMC11376108 | biostudies-literature
| PRJNA699853 | ENA
| PRJNA699852 | ENA
| S-EPMC4586885 | biostudies-literature